NEWS SUMMARY: CHANGES IBEX 35, GRUPO CATALANA OCCIDENTE, INDRA, SACYR. Stock markets on stand by European stock markets saw a second session of stability, awaiting the Fed’s decision to be made public tomorrow. In the STOXX 600, Insurance and Household led the gains whereas Pharma and Constructions were the worst performers. On the macro side, the ECB will propose merging the systemic risk buffer and the countercyclical capital buffer instead of reducing the capital buffers demanded of banks. I...
COMPAÑÍAS QUE APARECEN EN EL INFORME: ESPAÑA: CAMBIOS IBEX, GRUPO CATALANA OCCIDENTE, INDRA, SACYR. Bolsas en stand by Segunda sesión de estabilidad en las bolsas europeas, a la espera de la decisión de la Fed de mañana. En el STOXX 600, los mejores sectores fueron Seguros y Hogar mientras que Farma y Construcción quedaron con las mayores correcciones. Por el lado macro, desde el BCE se propondrá fusionar el colchón de riesgo sistémico y el colchón de capital anticíclico en lugar de reducir los...
Today, we are publishing the Automotive section of our 29th Tech Infrastructure Quarterly Bible. The Tech Bible is a must-read for any tech investor, as it summarizes the quarterly earnings reports from the over 140 companies we track, providing an update on our key perspectives and convictions. We will publish sections on Hyperscale & Cloud, Telecom Equipment, Industrials, PCs, Enterprise IT, and Foundry later this week. Auto demand came in above expectations, with limited signs of an air-pock...
3Q'25 vs. 3Q'24 Results Sales: € 1.175 Bn (2.8% vs. 3.1% BS(e) and 1.3% consensus); EBITDA: € 371 M (27.7% vs. 23.0% BS(e) and 20.1% consensus); EBIT: € 273 M (1.2% vs. 15.2% BS(e) and 20.2% consensus); Net Profit: € 31 M (41.5% vs. 35.1% BS(e) and 70.7% consensus). 9M'25 vs. 9M'24 Results Sales: € 3.412 Bn (4.6% vs. 4.7% BS(e) and 4.0% consensus); EBITDA: € 1.018 Bn (7.4% vs. 6.0% BS(e) and 5.1% consensus); EBIT: € 737 M (-15.2% vs. -10.9% BS(e) and -9.3% consensus); Net Profit: € 62 M (-16.2%...
Rdos. 3T'25 vs 3T'24: Ventas: 1.175 M euros (2,8% vs 3,1% BS(e) y 1,3% consenso); EBITDA: 371 M euros (27,7% vs 23,0% BS(e) y 20,1% consenso); EBIT: 273 M euros (1,2% vs 15,2% BS(e) y 20,2% consenso); BDI: 31 M euros (41,5% vs 35,1% BS(e) y 70,7% consenso). Rdos. 9M'25 vs 9M'24: Ventas: 3.412 M euros (4,6% vs 4,7% BS(e) y 4,0% consenso); EBITDA: 1.018 M euros (7,4% vs 6,0% BS(e) y 5,1% consenso); EBIT: 737 M euros (-15,2% vs -10,9% BS(e) y -9,3% consenso); BDI: 62 M euros (-16,2% vs -18,2% BS...
NEWS SUMMARY: ACS, AMADEUS, CELLNEX, IAG, SACYR. At the end of today’s report, and during the entire results season, we will include a presentation with positive and negative results highlights and previews for the 3Q’25 results to be released over the coming days in Spain. Doubts persist With the results campaign entering the final stretch, the main European indices closed with losses, with the IBEX standing out as the best performer, remaining at around 16,100. In the STOXX 600, Basic Mate...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.